In patients with NSCLC receiving anti-PD-(L)1 therapy, a higher proportion of TCF1-expressing T cells was observed in the circulating CD8+ Tem cells of patients who achieved durable clinical benefit (DCB) at baseline than in those who were resistant to treatment. Here, CD8A is linked to non-small cell lung carcinoma.